Product Profiles: Alzheimer's Disease - Immunotherapies can revolutionize treatment paradigmPublished by: MarketLine Published: Nov. 3, 2011 - 150 Pages Table of Contents
AbstractIntroductionThe beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing to an absence of new market entrants over the past decade. However, given the weight of candidates with disease-modifying potential in the pipeline, new drugs are expected to emerge that will satisfy one of the biggest unmet needs in the industry – a treatment that slows Alzheimer’s disease neurodegeneration. Features and benefits
Datamonitor’s physician survey reveals that Aricept finds widespread use across all lines of therapy and severities, from mild cognitive impairment to severe Alzheimer’s disease. However, Eisai faces a steep decline in revenues as generic donepezil take hold in the US, marketed competition heightens in Japan, and European patents near expiry.Bapineuzumab and solanezumab have the potential to revolutionize Alzheimer’s disease treatment and become future market leaders. However, each program carries a caveat. J&J/Pfizer are relying on post-hoc analyses of bapineuzumab in a subpopulation while Lilly is betting on solanezumab’s Phase II biomarker effect translating into tangible benefits.A precedent already exists for neurotransmitter mechanisms, ensuring a higher likelihood of navigating through clinical trials. Late-stage symptomatic drugs include Eisai’s Aricept patch and GSK’s 5-HT6 receptor agonist SB-742457, although the potential rewards on offer for these candidates are lower than for the immunotherapies. Your key questions answered
Get full details about this report >> |
|
|
|
About MarketResearch.com
|
||
|
|
On the WEB
1/18/2013 - 32